Introduction {#S1}
============

Alzheimer's disease (AD) is an as of yet incurable neurodegenerative disorder ([@B150]). Its cardinal features are senile plaques formed by nonvascular extracellular deposits of amyloid fibrillary amyloid beta (Aß) and intra-neuronal neurofibrillary tangles (NFT) consisting of aggregates of hyperphosphorylated tau protein ([@B79]; [@B48]). The amyloid cascade hypothesis posits Aβ is the cause of AD, triggering the formation of NFT, neuronal cell loss, vascular damage, and dementia ([@B150]). In the modernized version of the amyloid cascade hypothesis, rather than senile plaques it is now thought that soluble Aβ oligomers (AßO) are the major driver of AD. Aβ peptides result from enzymatic cleavage of the disease-associated amyloidogenic processing of APP ([@B134]). Aβ peptides of different lengths can seed formation of AßO, protofibrils, fibrils, and senile plaques ([@B102]; [@B92]; [@B150]; [@B48]; [@B138]). The 40 (Aβ40) and 42 (Aβ42) amino acid length peptides are the most intensely studied, with Aβ42 being the most amyloidogenic.

Beyond the fact that extracellular Aβ deposits are a pathological diagnostic hallmark ([@B79]), genetic data supporting the amyloid cascade hypothesis is rather powerful ([@B150]). Clinical trial "failures" of Aβ-depleting antibodies are also powerful argument against the hypothesis ([@B92]; [@B138]). There are several antibodies designed to target Aβ, which in turn elicit their putative therapeutic effects by targeting different species of Aβ ([@B138]). Clearance of amyloid plaques by AN-1792 did not prevent disease progression ([@B75]). As noted, neurotoxicity is thought to depend on AβO ([@B150]). Adecanumab targets the neurotoxic effects associated with oligomers as well as prompting the dissolution of Aβ plaques ([@B151]; [@B138]). Despite this, by the first quarter of 2019 the Aducanumab ENGAGE (NTC02484547) and EMERGE (NTC02477800) trials were halted as a result of futility analysis ([@B149]).

In the wake of this mounting discouraging clinical evidence, encouraging reports simultaneously begun to emerge supporting a new class of drugs known as senolytics as a novel therapeutic avenue for AD ([@B26]; [@B129]; [@B182]). Senolytics elicit the selective killing of senescent cells ([@B95]) and there was already proof of concept for their potential use in Parkinson's disease (PD; [@B36]). Most senescent cells develop a senescence associated secretory phenotype (SASP) involving the secretion of cytokines, chemokines, mitogenic factors, and proteases that can damage the surrounding microenvironment ([@B2]; [@B42], [@B40],[@B41]; [@B99]; [@B133]). Senolytics eliminate senescent cells and therefore the SASP ([@B95]). Within the context of AD, proof of concept for senolytic therapies was first provided in mice expressing wild type or mutated human tau isoforms but lacking Aβ pathology ([@B26]; [@B129]). A role for Aβ in the development of cellular senescence was rejected ([@B129]). Paradoxically a senolytic intervention was later proven successful in transgenic mice presenting Aβ without tau pathology ([@B182]), underscoring that each of the proposed mechanisms of action of senolytic intervention are radically different.

Unexpectedly, by the last quarter of 2019 a subgroup of patients receiving high-dose Aducanumab treatments were claimed to have met its target outcomes in prodromal and early AD patients. Although not free of skepticism ([@B149]), this has prompted the re-launch of a clinical trial to assess high dose Adecanumab to begin in March 2020 (NCT04241068). It is possible that Aβ may trigger a pathological cascade of events that may evolve on its own independent of the continued presence of Aβ and therefore its clearance after the cascade has already been set in motion may be too late ([@B150]). Implementing early intervention in AD is particularly complex considering that the first signs of Aβ pathology can precede clinical AD by 15 to 25 years ([@B15]; [@B168]; [@B167]). Both proponents and detractors of the amyloid cascade hypothesis seem to be in agreement on one thing; Aβ clearance is not likely effective in mild-to-moderate clinical AD. Antibodies such as Aducanumab may therefore only be effective at early stages, prior to the activation of the cascade. We arguably need to shift to therapies suppressing the cascade and yet we do not know what the cascade is. As we will review, the cascade may be senescence itself.

Cellular Senescence {#S2}
===================

Senescence is traditionally regarded as an oncosuppressive mechanism that imposes an irreversible cell cycle withdrawal ([@B62]). The classical senescence-inducing stressor is DNA damage signaling associated to telomere attrition, better known as replicative senescence (RS; [@B68]; [@B62]). RS marks the end of the replicative lifespan of the cell, but cells can undergo senescence before reaching it. This is often termed stress-induced premature senescence (SIPS). Multiple stressors can result in SIPS including reactive oxygen species (ROS), oncogenes, and ionizing radiation (IR; [@B62]). Although there are exceptions, most stressors result in SIPS by causing persistent DNA damage either directly or indirectly ([@B3]; [@B55]; [@B185]; [@B176]; [@B62]). ROS and IR can directly elicit DNA damage, while oncogenes often--albeit not invariantly-do so indirectly by aberrantly activating the DNA replication machinery ([@B67]; [@B103]; [@B62]). SIPS is often associated with cell cycle dysregulation but nevertheless cells that are not mitotically active can undergo senescence ([@B163]; [@B3]).

Evidence for SIPS in neurons and non-neuronal cell types has been provided in *in vitro* and *in vivo* models of AD ([@B19]; [@B69]; [@B182]), and senescence markers have been described in neurons of AD patients ([@B8], [@B7]; [@B118]; [@B114]). As we will argue, there is reasonable evidence that AβO is a SIPS-inducing stressor. Senescence is a largely irreversible phenotype ([@B62]). It follows that the clearance of AβO should prevent the onset of cellular senescence but not revert it once it is established. If senescence is the actual cascade of the amyloid cascade hypothesis it may be largely irrevocable, potentially explaining the failure of some Aβ-targeting antibodies in clinical trials.

Senescence Markers {#S3}
==================

Although it is not always the case, when it comes to neurons it is common to see use of the term "senescent-like phenotype" ([@B171]). Senescent-like is a conservative denomination that reflects potentially insurmountable challenges in the study of senescence in neurons.

There are no universal markers of senescence and therefore use of a single senescent marker is not a reliable mean of proving senescence in any cell type ([@B72], [@B73]; [@B62]). For example, a widely used senescence marker in non-neuronal cells is senescence-associated-beta-galactosidase (SA-ß-Gal; [@B46]). However, SA-ß-Gal has been shown to be up-regulated in neurons that lack other senescence markers ([@B142]; [@B129]; [@B171]). SA-ß-Gal is lysosomal and reflects the increased lysosomal mass in senescent cells but is not necessary nor causes senescence ([@B100]; [@B104]; [@B73]; [@B62]). SA-ß-Gal in neurons has indeed been argued to simply reflect senescence-unrelated lysosome biogenesis ([@B142]; [@B129]; [@B171]). In order to prove neuronal senescence, multiple markers of senescence should be used which may include p16^INK4A^, p21^CIP1^, Lamin B1, HMGB1, and amongst others ([@B73]; [@B62]). The phenotype should also be relatively stable, as cellular senescence is considered an irreversible phenotype. With the aforementioned in mind, we propose that: 1. Multiple senescence markers need to be used to assess senescence in neurons; 2. The mechanism of action of any identified senescence-inducing stressor should be consistent with that in mitotically-competent cells; and 3. The phenotype should still persist after the senescence-inducing stressor has been removed. If successfully demonstrated, this would provide a convincing characterization of neuronal senescence.

Arguably the gold standard for identifying cellular senescence is demonstrating an irreversible block on cellular proliferation. Normally differentiated neurons never proliferate under physiological conditions ([@B54]). When non-physiological means are used to force neuronal cell division, the rate of success is under 5% and thus far entails detection of only a single cell division ([@B172]). Because neurons in general do not proliferate, it is not possible to prove that an irreversible block on proliferation is caused by senescence rather than their native postmitotic state. The best we can hope for is to characterize a senescent-like phenotype that is consistent with senescence. Nevertheless, given that this review concerns several cell types, to avoid cumbersome phrasing we will hereafter use the term "senescence" for neurons, and glial cells alike.

Neuronal Cell Cycle Entry in AD {#S4}
===============================

Aberrant cell cycle entry in neurons of AD patients is well established ([@B54]). It is important to distinguish this from adult neurogenesis. Adult neurogenesis entails the physiological proliferation of neuronal precursor cells (NPCs), which latter differentiate into two specific neuronal types in very restricted niches ([@B64]; [@B94]). In contrast, aberrant activation of the cell cycle in AD patients takes place within neurons and is strictly pathological ([@B54]). Cell cycle reactivation in neurons of AD patients does not result in cell division ([@B54]). Neurons in the brains of AD patients have been shown to survive for extended periods of time after cell cycle entry ([@B6]). This is consistent with cells having undergone cellular senescence after an abortive cell cycle ([@B93]; [@B67]; [@B170]; [@B83]). In support of this, up-regulation of the senescence marker p16^INK4A^ was reported within pyramidal neurons of AD patients in several older historic studies, suggesting the potential involvement of senescence in AD as early as two decades ago ([@B8], [@B7]; [@B118]; [@B114]).

Given that potential evidence for senescence in AD patients has existed for years, it is somewhat curious that research of senescence in neurobiology is only now blooming ([@B171]). The historic paucity of studies of senescence in AD may be explained by a misunderstanding of mitotic cell biology. For many years, forcing primary neurons in culture to enter the cell cycle resulted in cell death ([@B54]). In one way or another, many thought that cell death was a consequence of the postmitotic status of neurons, likely influenced by the erroneous presumption that mitotically-competent cells never undergo cell death upon cell cycle entry. Oncogenes can and do force cell cycle entry in mitotically-competent cells, where cell death is an indispensable response to prevent carcinogenic cell division ([@B93]; [@B25]; [@B67]; [@B170]; [@B83]). The first *in vitro* models of an abortive cell cycle with viable exit were achieved by inactivating the same machinery that causes oncosuppressive cell death and senescence in mitotically-competent cells ([@B12]; [@B172]). Hence, cell death after forced cell cycle suggests that neurons possess at least one of two major oncosuppressive mechanisms present in virtually all mitotically-competent cells. The other described mechanism for oncogenic suppression is cellular senescence ([@B93]; [@B67]; [@B170]; [@B35]; [@B83]; [@B103]; [@B62]).

As noted, senolytics have been demonstrated to have a therapeutic effect in a tau transgenic mice models ([@B26]; [@B129]). Whether it is the killing of senescent neurons or senescent glia remains unclear ([@B171]). In the case in which it was argued that senescent neurons were killed, it was speculated that senescence was caused by NFT mediated cell cycle entry ([@B129]). Indeed, there are some reports of tau-induced cell cycle entry in neurons ([@B4]; [@B20]; [@B82]; [@B152]; [@B76]), albeit entry mediated by NFT has been contested ([@B82]), and at least in some cases it involves Aβ ([@B152]; [@B76]). When compared to tau-related models, cell cycle deregulation has been vigorously researched in models of Aβ pathology ([@B37], [@B38]; [@B60], [@B59]; [@B139]; [@B177]; [@B98]; [@B159]; [@B179]; [@B29]; [@B115]; [@B165], [@B164]; [@B18]; [@B109], [@B110]; [@B106]; [@B122], [@B121]; [@B153]; [@B76]; [@B120]; [@B30]; [@B105]; [Table 1](#T1){ref-type="table"}). Virtually all reports report cell cycle related cell death, which is of relevance for senescence. As noted above, aberrant cell cycle activation should result in cell death or senescence. For example, the E2F1 transcription factor, a major driver of G1/S transition, can also result in cell death or senescence if aberrantly activated ([@B84]). Fittingly, Aβ-mediated cell death is at least in part mediated by E2F1 ([@B60], [@B59]). It may be argued that if aberrant cell cycle entry is the means by which neurons senesce in AD, Aβ is the most likely cause.

###### 

Literature describing cell cycle entry downstream of Aβ treatment or in mouse models of AD.

                                                                 Max Percent Putative Cell Cycle Entry Reported                        
  --------- --------- ------------ ------------------ ---------- ------------------------------------------------ ---------- --------- ---------
  [@B37]              8--12 DIV    DNA content        Ref Cult   2--10%                                           2--10%     2--10%    0.1--2%
  [@B177]   Culture   5--8 DIV     BrdU               MAP2       2--10%                                                                2--10%
  [@B39]    Culture   8--9 DIV     DNA content        Ref Cult   2--10%                                                                0.1--2%
  [@B159]   Culture   NS           DNA content        Ref Cult   10--20%                                                               0.1--2%
  [@B98]    Culture   4--8 DIV     DNA Content        MAP2                                                                   10--20%   2--10%
  [@B38]    Culture   8--12 DIV    DNA Content        Ref Cult   2--10%                                                                0.1--2%
  [@B115]   Culture   Adult mice   Cyclin D1 IHC      NS                                                                     50--75%   0.1--2%
  [@B115]   Culture   Adult mice   Cyclin B1 IHC      NS                                                                     20--50%   0%
  [@B29]    Culture   8--11 DIV    DNA Content        Ref Cult   2--10%                                                                0.1--2%
  [@B165]   Culture   7--8 DIV     BrdU               MAP2                                                                   20--50%   2--10%
  [@B165]   R1.40     6--12 M      Cyclin A                      R1.40                                            20--50%              0--10%
  [@B165]   R1.40     6--12 M      Cyclin D                      R1.40                                            50--75%              0--10%
  [@B165]   R1.40     6--12 M      Polyploid                     R1.40                                            10--50%              0--10%
  [@B18]    Culture   21--22 DIV   BrdU               MAP2                                                                   20--50%   2--10%
  [@B18]    Culture   21--22 DIV   BrdU               MAP2       R1.40                                            20--50%              10--20%
  [@B164]   R1.40     6 M          Cyclin D           NeuN       R1.40                                            20--50%              
  [@B164]   R1.40     6 M          Cyclin A           NeuN       R1.40                                            20--50%              
  [@B164]   R1.40     6 M          Polyploid          NeuN       R1.40                                            10--20%              
  [@B110]   WT ICV    8 W          Cdk4 IHC HP        NS                                                          10--20%              2--10%
  [@B110]   WT ICV    8W           Cyclin D1 IHC HP   NS                                                          2--10%               2--10%
  [@B106]   R1.40     6--12 M      PCNA                          R1.40 (HP)                                       15--30%              0--5%
  [@B106]   Tg2576    9--11 M      PCNA                          Tg2576 (HP)                                      0--5%                0--5%
  [@B106]   5XFAD     6 M          PCNA                          5XFAD (HP)                                       0--5%                0--5%
  [@B106]   APP8.9    14 M         PCNA                          APP8.9 (HP)                                      0--5%                0--5%
  [@B106]   APP/PS1   6--7 M       PCNA                          APP/PS1 (HP)                                     0--5%                0--5%
  [@B122]   Culture   5 DIV        BrdU               NS                                                                     20--50%   2--10%
  [@B76]    3xTgAD    5--16 M      ppRb807            NS         3xTgAD                                           0.1--10%             
  [@B76]    3xTgAD    18--20 M     ppRb807            NS         3xTgAD                                           20--50%              
  [@B76]    3xTgAD    5--16 M      ppRb807            NS         3xTgAD                                           0.1--10%             
  [@B76]    3xTgAD    18--20 M     ppRb807            NS         3xTgAD                                           20--50%              
  [@B120]   Culture   NS           DNA Content        Ref Cult                                                    10--20%              2--10%
  [@B120]   Culture   NS           Cyclin A2 ICC      NS                                                          2--10%               2--10%
  [@B121]   Culture   NS           BrdU               NS                                                                     10--20%   0.1--2%
  [@B105]   WT ICV    7 weeks      Cyclin A2 IHC Cx   NeuN                                                                   20--50%   2--10%
  [@B105]   WT ICV    7 weeks      Cyclin A2 IHC Hp   NeuN                                                                   20--50%   10--20%

We have not included research that assess cell cycle entry by bulk analysis (e.g., Western Blot, qPCR) as neuronal cultures invariantly have astrocyte contamination and brain lysates also contain glial cells. Consequently, distinguishing cell cycle activity in neurons from that of other cells is not possible. The models we have included are neuronal cell cultures (Culture), transgenic AD mouse models (R1.40, Tg2576, 5XFAD, APP8.9, APP/PS1, and 3xTgAD), and acute AD mouse models based on intracerebroventricular microinjection of Aβ peptides (ICV). "Method" refers to the manner in which cell cycle entry was assessed. Certain cell cycle markers are present under basal conditions and thus the data should be interpreted with caution. "Neuron marker" refers to the manner in which the authors have identified neurons to separate them from contaminating glial cells. "Ref Cult" is Reference Culture and alludes to cultures in which neuronal markers have been used to estimate glial cell contamination. Putative percent cell cycle entry is approximate. Aβ isoforms cannot be identified in transgenic models and therefore is not specified. Days in vitro (DIV), immunohistochemistry (IHC), hippocampus (Hp), cortex (Cx), and immunocytochemistry (ICC).

Aβ, ROS, and Senescence {#S5}
=======================

Amyloid beta pathology models have been used to study senescence despite the lack of studies in neuronal cell cycle dysregulation. Aβ peptide administration is shown to induce senescence in astrocytes *in vitro* and the number of astrocytes with a senescent phenotype are increased in AD patients ([@B19]). Increased expression of p16 is reported in neurons of an AD mouse model and AβO reportedly increase p16 levels *in vitro* ([@B175]). Mechanisms involving ROS are known to induce senescence in mitotically competent cells ([@B62]). AβO exposure induces senescence via ROS in NPCs from wild type (WT) and AD mouse models ([@B69]). DNA damage can result in persistent DDR and p21-mediated mitochondrial dysfunction leading to increased ROS production ([@B140]). ROS regenerates DNA damage, locking cells into senescence. A similar senescent-like phenotype has been described in the neurons of aging mice ([@B86]). Thus, increases in ROS downstream of AβO is a plausible mechanism for senescence induction.

There is extensive research linking Aβ to ROS in neurons. Extracellular actions of AβO elicits neurotoxic effects via ROS production and Ca^2+^ dysregulation by binding to N-Methyl-D-Aspartate receptor (NMDAr) on excitatory synapses ([@B44]; [@B101]; [@B154]; [@B66]; [@B156]). In fit, toxic, or physiological ROS levels are produced downstream of NMDAr excitotoxic or normal activation, respectively ([@B50]; [@B144]; [@B174]; [@B24]). AβO exposure *in vitro* induces ROS and JNK pathway activation ([@B88]), up-regulation of p38, and Ca^2+^ influx ([@B49]). Intracellularly-acting AβO has been associated with oxidative stress and ROS production via mitochondrial dysfunction, Ca^2+^ perturbation, and trace element interactions. AβO impacts mitochondrial dysfunction via inhibition of nuclear protein import ([@B155]; [@B31]), abnormal fission and fusion dynamics ([@B13]; [@B181]; [@B78]), ATP synthase activity impairment ([@B148]; [@B32]; [@B16]), and an up-regulation of mitochondrial production of ROS ([@B145]; [@B116]; [@B124]; [@B90]; [@B78]; [@B52]). AβO accumulation within the mitochondria directly interacts with ABAD and cyclophilin D, promoting ROS leakage, membrane potential change, and Ca^2+^ dysregulation ([@B112]; [@B70]; [@B123]). Perturbation of mitochondrial or endoplasmic reticulum (ER)-mediated Ca^2+^ homeostasis may underlie intracellular-mediated Aβ excitotoxicity. Intracellular AβO modulates resting cytosolic free Ca^2+^ levels ([@B147]; [@B47]; [@B125]; [@B81]), remodels intra-organellar Ca^2+^ by disruption of mitochondria-associated ER membranes (MAMs; [@B125]), and alters Ca^2+^ release from internal stores ([@B147]; [@B125]; [@B28]; [@B81]), which can lead to ROS formation and further pathological oligomerization of Aβ ([@B88]; [@B119]; [@B90]; [@B21]). Further, production of ROS can be mediated by Aβ interaction with transition metals, specifically copper or iron, to produce hydrogen peroxide, and superoxide via Fenton reaction ([@B85]; [@B33]; [@B117]; [@B27]; [@B61]). AβO-dependent increase in ROS and activation of the cell cycle machinery are alternative ways in which AβO can induce potentially senescence in several cell types ([Figure 1](#F1){ref-type="fig"}).

![Diagram depicting possible ways in which AβO can induce senescence in neurons and or glial cells. AβO can induce unscheduled cell cycle entry in neurons leading to senescence (a). AβO can also induce ROS, either downstream of aberrant activation of post-synaptic receptors (e.g., NMDAr) in neurons (b) or independent of receptor activation in neurons and or glial cells (c). Senescent neurons and or glial cells may develop the SASP. SASP factors released from senescent neurons and or glial cells can result in inflammation and secondary senescence, spreading the disease. Major SASP regulators p38 and NF-kB may also elicit tau hyperphosphorylation, potentially linking the SASP to NFTs in neurons.](fncel-14-00129-g001){#F1}

The Deleterious Effects of Senescence {#S6}
=====================================

Within a senescence-based hypothesis of AD, the consensus is that the SASP is the culprit for subsequent observed disease phenotypes ([@B26]; [@B129]; [@B171]; [@B182]). Although the SASP is a very heterogeneous phenotype ([@B14]), secreted components often include interleukin IL-6, chemokine IL-8, or TGFβ ([@B40]; [@B133]; [@B62]). Prominent SASP regulators include p38MAPK, NF-kB C/EBPβ, GATA4, and mammalian target of rapamycin (mTOR). Senescent markers are up-regulated in the astrocytes of AD patients and Aβ has been reported to elicit senescence in astrocytes *in vitro* via ROS accompanied by p38, IL-6, and IL-8 up-regulation ([@B19]). Further, oligodendrocyte precursor cells (OPC) in an AD mouse model show a pro-inflammatory phenotype along with increases p16 and p21 expression near Aβ plaques and Aβ can induce senescence in cultured OPCs ([@B182]). IL-6 and TGFβ mRNA are upregulated in AD patients ([@B113]; [@B65]), but inflammatory response from resident immune cells is also prominent in AD and cannot be ruled out ([@B71]). However, active p38 overlaps and immunoprecipitates with NFT from neurons of AD patients, but not from healthy controls ([@B184]). Aβ activation of p38 has been placed upstream of pathological tau phosphorylation in neuron cultures ([@B137]; [@B127]). Aβ activates NF-kB in primary neurons and is found in astrocytes and neurons in proximity to senile or diffuse plaques as well as NFT-positive neurons in AD patients, but not in healthy controls ([@B161]; [@B89]; [@B53]; [@B157]). A "senescent-like" phenotype described in neurons of aging mice involves p38, ROS and intraneuronal IL-6 suggesting neurons may develop a "SASP-like" phenotype during normal aging ([@B86]), which, in light of aforementioned evidence, could be exacerbated in AD.

It is plausible that AβO can result in senescence, with subsequent increases in p38 and NF-kB activity reflecting the development of the SASP. Given the association of active p38 and NF-kB with NFTs ([@B127]; [@B65]), tau pathology may be part of the SASP and therefore a feature of senescence whether the latter is caused by Aβ or not ([Figure 1](#F1){ref-type="fig"}). Hence, the cascade of the amyloid cascade hypothesis may be irreversible if it is indeed cellular senescence and deleterious if it also involves the SASP.

Secondary Senescence {#S7}
====================

Senescent cells can induce senescence in neighboring non-senescent cells via a process known as paracrine senescence or secondary senescence (hereafter secondary senescence; [@B62]). Secondary senescence is dependent on SASP factors and has been shown to be transmitted by either diffusible factors, gap-junctions, or both ([@B77]; [@B132], [@B131]; [@B1]; [@B87]; [@B43]). It may be expected that a population of senescent astrocytes, microglia, OPCs, and or NPCs radiate away from Aβ foci by secondary senescence. Consequently, these senescent cells would be expected to be found near regions of Aβ burden but not necessarily elsewhere, which does not appear to be consistent with what is known about AD progression. Senile plaques and NFT in AD largely follow a stereotypical pattern of neuroanatomical distribution ([@B79]; [@B48]). This has led to the Thal staging of amyloid phases ([@B162]) and the Braak staging based on hyperphosphorylated tau and NFTs ([@B23]; [@B22]). In Braak stages I and II, NFTs first develop in the trans-entorhinal cortex and layers two and four of the entorhinal cortex. In stages III and IV, NFT burden is also present in the hippocampus. In the last phase, and stages V and VI, tau pathology is spread to the neocortex. Paradoxically, the neocortex is the first site of Aβ deposits in Thal phase 1 ([@B162]). In phase 2/3 there is a spread to allocortical brain regions, including the hippocampus and entorhinal cortex. Stage 3, 4, and 5 entail a spread into subcortical and cerebellar regions. Albeit not impossible, this progression is hard to reconcile with the spread of AD neuropathology being driven by senescent astrocyte, microglia, OPCs, and or NPCs. In contrast, neurons emit long-range axonal projections that can span the entire brain. If cortical neurons senescence and develop the SASP in response to AβO, then SASP and secondary senescence can reach distant regions that are free of Aβ. Importantly, the trans-entorhinal region converges widespread afferent projections from the neocortex ([@B169]). At least in theory, a sparse population of neocortical senescent neurons spawned by diffuse AβO can converge their axonal projections into trans-entorhinal and entorhinal cortices, potentially allowing spread of the SASP and secondary senescence from the entire cortex. While cellular senescence and the SASP may, respectively, render the amyloid cascade irreversible and deleterious, secondary senescence can explain why the cascade results in the striking topographical spread of AD neuropathology.

Senescence Immune Surveillance and Immune Privilege {#S8}
===================================================

Outside the central nervous system (CNS) senescent cells are normally cleared by the innate immune system ([@B111]). Senescent cells have been shown to be cleared by natural killer cells (NKs; [@B80]; [@B51]; [@B146]; [@B5]; [@B126]; [@B141]) and macrophages ([@B178]; [@B97]; [@B91]; [@B128]). The way in which NKs kill senescent cells in the periphery is well-understood ([@B5]). The activation of NKs depends on a complex interplay between their activator and inhibitory receptors. Specifically, human senescent cells up-regulate MICA, and ULBP2, ligands for the stimulatory receptor NKG2D ([@B5]). Given the CNS is under immune privilege, T-cells, NKs, and peripheral macrophages normally have limited access to the meninges and choroid plexus and far-limited access to the CNS parenchyma ([@B56]; [@B96]; [@B17]). Thus, regardless of which CNS cell types undergo senescence, the clearance of senescent cells is likely limited in healthy non-aged individuals. Senescence cells, the SASP and secondary senescence, may therefore continue in the brain for years to decades.

A feature of aging that is exacerbated in AD is the progressive dysfunction of the blood brain barrier (BBB) resulting in immune cell infiltration ([@B63]; [@B160]; [@B130]). In AD, the question arises as to whether loss of immune privilege with advancing age eventually enables immune cells to kill senescent that have accumulated for years in the CNS. Infiltrating monocytes and their derived macrophages have been studied in AD ([@B74]), albeit their role is unlikely linked to senescent cell killing. In as far as microglia are considered CNS resident macrophages, a case for microglia-mediated killing of senescent cells could potentially be made. This would require infiltrating CD4^+^ T-cells, as peripheral macrophages appear to depend on these cells to kill senescent cells outside the CNS ([@B91]). To the best of our knowledge, there is no evidence that microglia selectively kill senescent cells. Studies have focused on infiltrating CD8^+^ T-cells in AD ([@B108]), some with surprising results ([@B58]), yet these are cells from the adaptive immune system that do not seem to play a relevant role in senescence immune surveillance ([@B5]). With regards to NK cells, studies in AD patients and AD mouse models have assessed peripheral but not infiltrating NKs ([@B158]). Unfortunately, from these studies it is hard to infer what may be happening within the brain parenchyma.

There is abundant evidence that NK cells can infiltrate and kill brain cells under other pathological conditions such as ischemia and NK are known to kill stressed neurons in co-culture ([@B9], [@B10]; [@B143]; [@B57]; [@B183]; [@B107]; [@B173]). Interestingly, under non-stressed conditions primary hippocampal neurons have been reported to be protected against NK cell killing by the lack of expression of NKG2D ligands ([@B9], [@B10]). These same stress ligands are up-regulated in senescent cells and target them for killing by NKs ([@B5]). Whether NKs can infiltrate the brain at latter stages of the disease and selectively eliminate senescent neurons, astrocytes or other CNS cell types will require further studies, although existing data fits with this possibility.

Current Conflicts and Future Directions {#S9}
=======================================

Evidence that senolytic intervention may be an effective treatment for AD was first reported in tau transgenic mice models of frontotemporal dementia (FTD; [@B26]; [@B129]), which do not present amyloid plaques but are arguably an AD-like tau pathology model. Shortly thereafter, senolytics were proven therapeutic in APP/PSEN1 AD transgenic models which present plaques but not tau pathology ([@B182]). The beneficial effects of senolytic intervention are attributed to either the selective killing of senescent astrocytes and microglia--not neurons-([@B26]) or the selective killing of neurons--not astrocytes-([@B129]) in these tau models and to the selective killing of senescent OPCs --not astrocytes nor microglia-in the APP/PSEN1 AD model ([@B182]). The use of AD and FTD models may explain why senescent OPCs appear to be the culprit in the AD mouse model but not in the FTD models. The selective killing of neurons versus glial cells within the FTD models is harder to reconcile, albeit different transgenic tau models were used ([@B26]; [@B129]). The future of senolytics requires resolving the cell type that is killed, but more importantly whether they kill neurons or not ([@B171]). A prime objective in future studies should include a thorough brain-wide assessment of neuronal cell death after senolytic intervention.

Cdkn2a up-regulation as measured by qPCR was reported to be absent in 15 month old 3xTg-AD mice by [@B129]. Cdkn2a encodes not only the widely used senescence marker p16^INK4A^ but also p19^ARF^ (p14^ARF^ in humans), the latter of which can have opposing functions ([@B11]). [@B182] report an increase in Cdkn2a in Aβ-producing APP/PS1 transgenic mice crossed with the INK-ATTAC mice. The INK-ATTAC transgene expresses a fluorescent reporter from the p16 promoter which, contrary to qPCR, and allows identification of specific cell types transcribing p16. The conflicting results between the 3xTg-AD ([@B129]) and the APP/PS1 ([@B182]) mice can be resolved by considering reported temporal expression of intraneuronal versus extraneuronal Aβ species in the 3xTg-AD mice. Intraneuronal AβO is present at 6 months, followed by a dip in expression that is only fully restored at 20 months ([@B135]). While intraneuronal Aβ peptides are present at 6 months of age, extracellular Aβ is not readily evident until 18 months of age ([@B136]). Hence, at 15 month of age, neither extracellular nor intracellular AβO pathology is fully developed in the 3xTg-AD. Attention should be paid to the presence of monomeric, oligomeric, and fibrillary Aβ as well as whether it is intracellular and or extracellular. Particularly considering that extracellular amyloid plaques are a diagnostic hallmark of AD ([@B79]; [@B48]), some AβO act exclusively extracellularly ([@B102]), extracellular AβO preparations can interact with receptors and the plasma membrane itself ([@B34]), and kill primary neurons ([@B180]), alter synaptic functions ([@B166]), induce tau-hyperphosphorylation ([@B45]), and the vast majority of the *in vitro* experiments referenced above regarding ROS and the cell cycle are based on extracellular Aβ administration. Future work is needed to assess senolytic interventions in transgenic mice with combined Aβ and tau pathology at stages in which both extracellular and intracellular Aβ pathologies are fully developed.

Conclusion {#S10}
==========

Failure of Aβ antibody-mediated clearance in clinical trials challenging the amyloid cascade hypothesis occurred around the same time that senolytic interventions began emerging as a therapeutic alternative for the treatment of AD. Senescence and the amyloid cascade hypothesis have generally been presented as separate etiological phenomena during the progression of AD. This unfortunately has led to a disregard of the abundant literature that directly and indirectly supports the ability of AβO to induce cellular senescence. Aβ pathology models have been shown to induce senescence in astrocytes ([@B19]), OPCs ([@B182]), and NPCs ([@B69]). As discussed above, AβO has also been shown to induce aberrant cell cycle entry and ROS in neurons, placing it upstream of stressors that are known to induce senescence in mitotically-competent CNS cell types ([@B62]). Rather than senescence being an alternative etiology to the amyloid cascade hypothesis, we describe aspects of senescence that potentially allow substitution of the term "senescence" for "cascade" which we propose as a novel amyloid-senescence hypothesis ([Figure 2](#F2){ref-type="fig"}). Future studies will be required to determine whether senescence provides the "cascade" in the amyloid cascade hypothesis. However, based on the current literature, it is likely too early to reject an amyloid-senescence hypothesis out of hand.

![Proposed model of the amyloid-senescence hypothesis. **1.** AβO burden appears 15 to 25 years prior to clinical onset of AD. At this point, antibody-mediated clearance is effective. **2.** AβO causes foci of senescent neurons, astrocytes, microglia, OPCs, and or NPCs by inducing aberrant cell cycle entry and or persistent ROS and DNA damage. Senescence cells and the SASP cause oxidative stress, inflammation, and initial stages of cognitive impairment. At early stages, the BBB is healthy. NKs cannot access the brain parenchyma to clear senescent cells, which remain viable. Antibody mediated clearance of AβO is no longer effective because senescence is irreversible. Senolytics can stop disease progression **3.** Foci of senescent neurons from across the cortex project into the transentorhinal cortex, where deleterious SASP and secondary senescence builds for years to decades. The SASP is accompanied by tau hyperphosphorylation and NFT. Cognitive impairment is accentuated. If too many senescent neurons are present, senolytics may prove fatal as neurons cannot regenerate. Senostatics, which target the SASP without killing cells, are an alternative. **4.** Age-associated disruption of the BBB enables NK cell infiltration and the killing of a large pool of senescent neurons, astrocyte, microglia, OPCs, and or NPCs, increasing inflammation and marking the onset of clinical AD. Immune suppression may be the only viable alternative at this stage. Boosting acetylcholine levels can help suppress the NK cell response. Individuals with senile plaques and NFT with a healthy BBB may remain relatively spared.](fncel-14-00129-g002){#F2}
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